CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients - Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

American Heart Journal

Volumn 168, Issue 1, 2014, Pages

  Bergmeijer, Thomas O ^a   Janssen, Paul W A ^a   Schipper, Jurjan C ^b   Qaderdan, Khalid ^a   Ishak, Maycel ^a,b   Ruitenbeek, Rianne S ^a   Asselbergs, Folkert W ^b,c,d   Van'T Hof, Arnoud W J ^e   Dewilde, Willem J M ^f   Spanó, Fabrizio ^g   Herrman, Jean Paul R ^h   Kelder, Johannes C ^a   Postma, Maarten J ⁱ   De Boer, Anthonius ^j   Deneer, Vera H M ^a   Ten Berg, Jurriën M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ISALA HOSPITAL   (Netherlands)

^f AMPHIA HOSPITAL   (Netherlands)

^g MEANDER MEDICAL CENTER   (Netherlands)

^h ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

ⁱ UNIVERSITY OF GRONINGEN   (Netherlands)

^j UTRECHT UNIVERSITY   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; PRASUGREL; TICAGRELOR;

ADULT; ALLELE; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GENETIC TECHNIQUES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903134076     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.03.006     Document Type: Article

References (29)

1. S.D. Wiviott, E. Braunwald, and C.H. McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
2. Authors/Task Force Members, Steg PG, and James SK et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Eur Heart J 33 20 2012 2569 2619
3. J.W. van Werkum, A.A. Heestermans, and V.H. Deneer et al. Clopidogrel resistance: fact and fiction Future Cardiol 2 2006 215 228
4. N.J. Breet, J.W. van Werkum, and H.J. Bouman et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
5. A. Kubica, M. Kozinski, and G. Grzesk et al. Genetic determinants of platelet response to clopidogrel J Thromb Thrombolysis 32 2011 459 466
6. J.L. Mega, T. Simon, and J.P. Collet et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
7. J.P. Collet, J.S. Hulot, and A. Pena et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
8. A.M. Harmsze, J.W. van Werkum, and J.M. Ten Berg et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study Eur Heart J 31 2010 3046 3053
9. L. Wallentin, R.C. Becker, and A. Budaj et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
10. P.A. Gurbel, K.P. Bliden, and K. Butler et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
11. P.A. Gurbel, D. Erlinge, and E.M. Ohman et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy JAMA 2012 1 10
12. J.T. Brandt, S.L. Close, and S.J. Iturria et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436 (Pubitemid 350154353)
13. J.W. Eikelboom, S.R. Mehta, and S.S. Anand et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782 (Pubitemid 44268228)
14. R. Mehran, S. Pocock, and E. Nikolsky et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials JACC Cardiovasc Interv 4 2011 654 664
15. R.F. Storey, R.C. Becker, and R.A. Harrington et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes Eur Heart J 32 2011 2945 2953
16. M.J. Price, P.B. Berger, and P.S. Teirstein et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
17. D. Trenk, G.W. Stone, and M. Gawaz et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
18. J.P. Collet, T. Cuisset, and G. Range et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
19. J.L. Mega, S.L. Close, and S.D. Wiviott et al. Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
20. FDA FDA drug safety communication: reduced effectiveness of plavix (clopidogrel) in patients who are poor metabolizers of the drug. 2010-12-03(11-2013) http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm
21. J.D. Roberts, G.A. Wells, and M.R. Le May et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial Lancet 379 2012 1705 1711
22. P.G. Steg, S. James, and R.A. Harrington et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
23. L. Hakkaart-van Roijen, and C.A.M. Bouwmans Short form-health and labour questionnaire (SF-HLQ) 2013(11-2013):39. http://www.bmg.eur.nl/fileadmin/ASSETS/ bmg/english/iMTA/Publications/Manuals-Questionnaires/Handleiding. -SF-HLQ-september-2010-definitief.pdf 2010
24. L. Van Roijen, M. Essink-Bot, and M. Koopmanschap et al. Labour and health status in economic evaluation of health care Int J Technol Assess Health Care 12 3 1996 405 415
25. R. Mehran, S.V. Rao, and D.L. Bhatt et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium Circulation 123 2011 2736 2747
26. D.E. Cutlip, S. Windecker, and R. Mehran et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
27. A.W. Van't Hof, J. Ten Berg, and T. Heestermans et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (on-TIME 2): a multicentre, double-blind, randomised controlled trial Lancet 372 2008 537 546
28. College voor zorgverzekeraars (CVZ) Guideline for pharmaco-economic research (in dutch) 2006-04-01;2013(11-2013):22. http://www.cvz.nl/binaries/ content/documents/zinl-www/documenten/rubrieken/pakket/pakketbeheer/ 0604-richtlijnen-voor-farmaco-economisch-onderzoek/Richtlijnen+voor+farmaco- economisch+onderzoek.pdf 2006
29. K. Thygesen, J.S. Alpert, and A.S. Jaffe et al. Third universal definition of myocardial infarction J Am Coll Cardiol 60 2012 1581 1598